FRANCE – Tollys, a Lyon, France-based developer of TL-532, a synthetic specific agonist of Toll-like receptor 3 (TLR3) cancer immunotherapy, received over €1.5m ($1.6M) from Bpifrance as part of its deep tech financing program.
Funding consists of 50% non-dilutive funding and 50% long-term loans. The company will use the funding for the preclinical development of TL-532 in cancer immunotherapy. In May 2020, Tollys closed a round of financing totaling €2.3m ($2.5M), thereby enabling the company to support preclinical studies and regulatory toxicology for its TL-532 compound, in preparation for clinical development by late 2021/early 2022. Founded in 2015 by Philippe Guillot-Chêne, chief business officer, and Vincent Charlon, chief executive officer, Tollys is a biopharmaceutical company focused on innate immunity, particularly on the biology and modulation of the TLR3 receptor. The company is pioneering TL-532, a new cancer immunotherapy to treat various types of cancer. Tollys discovered and patented a family of TLR3 agonists and selected TL-532 as its lead-candidate. TL-532 is a structurally defined double-stranded RNA, produced synthetically and highly specific to the TLR3 receptor. The specificity for the TLR3 receptor and its defined 70 base pair sequence differentiates TL-532 from all other TLR3 agonists tested to date in clinical trials. Tollys has a staff of ten and has raised a total of €6.0M ($6.4M) from private investors. 06/07/2020
